newsfilter
← Latest News
Business Wire·

Dyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical Immunology Annual Congress

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that clinical data from its DX-2930 Phase 1b study was selected as a late-breaking abstract and presented on June 7, 2015 at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Barcelona, Spain. Discovered by Dyax, DX-2930 is an investigational fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.